Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Drug Information

Target Indication

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Clinical Trial

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Related Pipeline

Obesity

Breast Cancer

Myasthenia Gravis Generalised

Unresectable Hepatocellular Carcinoma

Duchenne Muscular Dystrophy